Skip to main content

Advertisement

Table 1 Clinical and pathological characteristics of breast cancer cases

From: Sulfatide decreases the resistance to stress-induced apoptosis and increases P-selectin-mediated adhesion: a two-edged sword in breast cancer progression

Parameter Patients GAL3ST1
IHC
(N = 232)
% IHC negative IHC positive p value (chi-squarea or Fisher exact testb)
Age
 ≤ 50 years 56 24.14 25 31 0.0904b
 > 50 years 176 75.86 102 74
Tumour grade
 G1 67 28.88 30 38 0.0215 b
 G2 96 41.38 53 42
 G3 55 23.71 38 17
 No data 14 6.03   
Tumour size
 pT1 119 51.29 66 53 0.8706b
 pT2 75 32.33 45 31
 pT3 4 1.72 2 2
 pT4 22 9.48 11 11
  14 6.03   
Lymph nodes
 pN0 87 37.50 53 34 0.4386b
 pN1–pN3 67 28.88 46 30
 pNx   0.00   
 No data 12 5.17   
Stage
 I 53 22.84 33 20 0.6406a
 II 60 25.86 35 25
 III 41 17.67 24 17
 IV 1 0.43 0 1
 No data 78 33.62   
Oestrogen receptor
 Negative 52 22.41 36 16 0.0203 b
 Positive 167 71.98 85 82
 No data 13 5.60   
Progesterone receptor
 Negative 69 29.74 40 28 0.4503b
 Positive 150 64.66 80 70
 No data 13 5.60   
HER2
 Negative 188 81.03 97 90 0.0894b
 Positive 34 14.66 23 11
 No data 10 4.31   
Molecular tumour types
 Triple negative 18 7.6 11 7 0.5492b
 Other types 199 85.78 107 92
 No data 10 4.31   
Chemotherapy
 Negative 13 5.60 8 5 0.7764b
 Positive 219 94.4 119 100
Hormonal therapy
 Negative 32 13.79 20 12 0.3398b
 Positive 198 85.34 103 95
 No data 2 0.8   
  1. Bold values (p < 0.05) are statistically significant
  2. HER2 human epidermal growth factor receptor 2, IHC immunohistochemistry, Gal3ST1 galactosylceramide sulfotransferase